Azione VERV VERVE THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Verve Therapeutics, Inc.

Azioni

VERV

US92539P1012

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 12/07/2024 		Variaz. 5gg Var. 1 gen.
6,73 USD +5,65% Grafico intraday di Verve Therapeutics, Inc. +28,19% -51,72%
28/06 Verve Therapeutics, Inc. annuncia la nomina del Consiglio di Amministrazione CI
10/06 Transcript : Verve Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
VERV The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc.
Verve Therapeutics : Potent, Specific, and Durable Liver Editing of PCSK9 in Preclinical Studies of the CRISPR Base Editing Medicine VERVE-101
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
Verve Therapeutics, Inc. Announces Board and Committee Appointments
VERV Investors Have the Opportunity to Join Investigation of Verve Therapeutics, Inc. with the Schall Law Firm
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Names Troy Lister Chief Scientific Officer
Verve Therapeutics, Inc. Announces Chief Scientific Officer Changes
Verve Therapeutics Announces Leadership Update
Verve Therapeutics, Inc. Announces Executive Changes
Verve Therapeutics to Participate in Upcoming Investor Conferences
Verve Therapeutics : An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise, and durable liver editing in nonclinical studies
Verve Therapeutics : Proof of concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL Cholesterol in Humans
Verve Therapeutics : Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off Target Editing with the Clinical Stage Base Editing Medicine, VERVE 101
Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket
Verve Therapeutics : Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off Target Editing with the Clinical Stage Base Editing Medicine, VERVE 101
Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Verve Therapeutics: Q1 Earnings Snapshot
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione VERV
  4. Notizie Verve Therapeutics, Inc.
  5. Altre lingue